Tamoxifen Doxorubicin

I 10. The answer is a. (Hardman, p 1302J Cyclophosphamide is classified as a poly functional alkylating drug that transfers its alkyl groups to cellular components. The cytotoxic effect of this agent is directly associated with the alkylation of components of DNA. Methotrexate and 5-FU are classified as anti metabolites that block intermediary metabolism to inhibit cell proliferation. Tamoxifen is an antiestrogen compound. Doxorubicin is classified as an antibiotic chemotherapeutic agent. 

Anticancer drugs Paclitaxel Docetaxel Vinblastine Vincristine Tipifarnib Diflomotecan Iiinotecan Doxorubicin Daunorubicin Etoposide Tenoposide Tamoxifen (i)... 

Although the endometrial cancers associated with tamoxifen are usually pure adenocarcinomas, other types of rare tumors have also been reported. A pure uterine rhabdomyosarcoma has been reported (99), and a mesodermal mixed tumor of the endometrium occurred 5 years after 5 years of tamoxifen therapy (100). The tumor responded only to combined treatment with doxorubicin, cyclophosphamide, 5-fluorouracil, and carbopla-tin. It is possible that this type of tumor arises later than adenocarcinomas and should be looked for during longterm use of tamoxifen. 

Vitamin E, in vitro, has been shown to enhance the cytotoxic effect of several anticancer drugs, including 5-fluorouracil (5-FU), doxorubicin, vincristine, dacarbazine, cisplatin, and tamoxifen. 

Carcinoma of breast (1) Adjuvant chemotherapy or tamoxifen after primary breast surgery Cyclophosphamide, doxorubicin, vincristine, methotrexate, fluorouracil, paclitaxel, mitoxantrone, prednisone, megestrol, androgens,1 aminoglutethimide, trastuzumab... 

Carcinoma of endometrium Progestins or tamoxifen Doxorubicin, cisplatin, carboplatin... 

The correct choice = B. Tamoxifen binds to the estrogen receptor and acts as an antagonist. Doxorubicin intercalates in DNA and thus interferes in transcription. Cyclophosphamide, mechlorethamine and cisplatin can cross-link with DNA strands to inhibit its function. 

ANTIARRHYTHMICS - disopyramide, propafenone 2. ANTIBIOTICS-chloramphenicol, doxycycline, metronidazole, rifampicin, telithromycin 3. ANTICANCER AND IMMUNOMODULATING DRUGS - carmustine, cidosporin, corticosteroids, doxorubicin, etoposide, ima-tinib, lomustine, paditaxel, tacrolimus, tamoxifen, toremifene, vinca alkaloids 4. ANTICOAGULANTS - ORAL 5. ANTI-... 

Black cohosh 2. Caffeine 3. Evening primrose oil 4. Scutellaria baicalensis 5. Starflower (borage) 1. Docetaxel 2. Paditaxel 3. Doxorubicin 4. Tamoxifen 5. Cisplatin 6. Vinorelbine t cytotoxic properties Unknown mechanism (black cohosh). Caffeine t cytotoxic effects of cisplatin wogonin present in Scutellaria enhances etoposide-induced apoptosis. Gamolenic acid found in evening primrose oil and borage potentiated the in vitro toxicity of paditaxel and vinorelbine, attributed to an unsaturated fatty acid as modulators of tumour cell chemosensitivity Be aware and avoid concomitant use... 

Actinomycin D, bisantrene, chlorambncil, cisplatin, cytarabine, dannornbicin, docetaxel, doxorubicin, epirn-bicin, etoposide, flnoro uracil, hydroxyurea, mitomycin C, mitoxantrone, paclitaxel, tamoxifen, topotecan, taxol, vinblastine, vincristine. 

The NCCN guidelines recommend retreatment with either paclitaxel or platinum, or the combination of paclitaxel and a platinum compound if disease recurs more than 6 months after the initial treatment with paclitaxel in combination with a platinum analog. Treatment options for patients with refractory disease or disease recurrence within 6 months after treatment include topotecan, altretamine, oral etopo-side, liposomal doxorubicin, gemcitabine, tamoxifen, referral for a clinical trial, or supportive care therapy. 

A4 Barbiturates, carbamazepine, corticosteroids, efavirenz, phenytoin, rifampin, troglitazone Antiarrhythmics, antidepressants, azole antifungals, benzc iazepines, calcium channel blockers, cyclosporine, delavirdine, doxorubicin, efavirenz, erythromycin, estrogens, HIV protease inhibitors, nefazodone, paclitaxel, proton pump inhibitors, HMG-CoA reductase inhibitors, rifabutin, rifampin, sildenafil, SSRIs, tamoxifen, trazodone, vinca anticancer agents... 

Breast carcinoma (stages 1 and II) CMP regimen Cyclophosphamide plus methotrexate and fluorouracil, or doxorubicin for methotrexate (CAP regimen) tamoxifen if hormone receptor-positive... 

Breast carcinoma Postoperative chemotherapy commonly involves use of the CMF regimen (cyclophosphamide, methotrexate, and fluorouracil) with or without tamoxifen, or the CAP regimen in which doxorubicin (Adriamycin) replaces methotrexate. Tamoxifen (or toremifene) is added to such regimens for receptor-positive cancers, and trastuzumab may be included if tumors overexpress HER2 protein. 

Items 1-3 A 32-year-old woman underwent segmental mastectomy for a breast tumor of 3 cm diameter. Lymph node sampling revealed two involved nodes. Since chemotherapy is of established value in her situation, she underwent postoperative treatment with antineoplastic dmgs. The FAC-V regimen was employed, consisting of fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide, plus vincristine. Six cycles 1 month apart of this chemotherapy regimen were planned. Adjunctive drugs included tamoxifen, since the tumor cells were hormone receptorpositive. 

Barbara, unemployed, formerly worked with the developmentally and mentally impaired. Breast cancer, stage 2, diagnosed in 2005 at age fifty. (Treatment mastectomy. Chemo doxorubicin, cyclophosphamide, pacli-taxel. Targeted therapy trastuzumab [Herceptin], Anti-hormonals tamoxifen, then anastrozole.)... 

Carol, former X-ray technician. Breast cancer, stage 2, diagnosed in 2001 at age forty-four. (Treatment bilateral mastectomies, radiation. Chemo doxorubicin, cyclophoshamide, and paclitaxel. Anti-hormonals initially tamoxifen, later aromatase inhibitors.)... 

Tamoxifen appears to have no significant effect on the pharmacokinetics of doxorubicin. 

A pharmacokinetic study in patients with non-Hodgkin s lymphoma receiving CHOP (cyclophosphamide, vincristine, prednisone and doxorubicin 37.5 to 50 mg/m ) found that the addition of tamoxifen 480 mg daily for 5 days had no significant effect on the AUC or total clearance of doxorubicin. For the possible additive thromboembolic effect of doxorubicin and tamoxifen, see Antineoplastics + Tamoxifen , p.616. 

El-Y arigi A, Berry J, Ezzat A, Wahab FA. Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin s l3nnphoma. TherDrugMonit( 991) 19,632-6. 

Solid lipid nanoparticles were originally developed for parenteral drug delivery to provide a parenteral drug carrier system based on physiological compounds and a potential controlled release and/or targeting of the drug. A broad variety of drugs (e.g. doxorubicin, camptothecin, etoposide, mitoxan-trone, tamoxifen,paclitaxel, clozapine, lovastatin, bromocriptine, temozolomide, actarit and dexametha-sone °) has already been incorporated into SLN formulations and tested in vivo in mice or rat. 

---